Cresp

What is Cresp?

Cresp is a long-acting biosimilar of darbepoetin alfa, developed by Dr. Reddy’s Biologics, used to treat anaemia by stimulating red blood cell production. It is indicated for patients with chronic kidney disease (CKD) and chemotherapy-induced anaemia, helping to manage symptoms and reduce the need for transfusions.

Visit website

Storage Conditions

2-8 degrees Celsius (refrigerate), Do not freeze.

Presentation

Vial/PFS containing drug

Route of Administration

Subcutaneous (SC) (upon prescription only).

Indications

Chemotherapy-Induced Anaemia (CIA):

Chemotherapy-induced anemia (CIA) is a common side effect of cancer treatment, particularly chemotherapy, where the drugs damage bone marrow cells responsible for red blood cell production, leading to a decrease in the number of red blood cells and the capacity to carry oxygen. In patients receiving chemotherapy for non-myeloid cancers, Cresp helps restore red blood cell counts, enhancing energy levels and supporting better tolerance of cancer treatments.

Chronic Kidney Disease (CKD):

Chronic Kidney Disease (CKD) is a condition where the kidneys are damaged and lose their ability to filter waste and excess fluid from the blood. Cresp is used to treat anaemia in CKD patients, both on dialysis and not on dialysis. It improves haemoglobin levels, reducing fatigue and improving the ability to perform daily activities.

Chemotherapy-Induced Anaemia (CIA):

How Darbepoetin Alfa works?

Mechanism of Action

Cresp works by stimulating red blood cell production through its active ingredient, darbepoetin alfa, a long-acting erythropoiesis-stimulating agent (ESA). It binds to erythropoietin receptors on progenitor cells in the bone marrow, activating the JAK-STAT signaling pathway, which promotes the proliferation and differentiation of these cells into mature red blood cells. The addition of extra carbohydrate chains in darbepoetin alfa prolongs its half-life, allowing for sustained activity and less frequent dosing compared to traditional erythropoietin. This extended duration of action makes it a convenient and effective option for managing anemia in chronic kidney disease and chemotherapy patients.